Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses leukocytoclastic vasculitis, particularly its triggers, manifestations, and treatments, and reports no new experimental results; the authors highlight valproic acid's association with this condition.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This study found that two injections of platelet-rich plasma were safe but no more effective than placebo in treating mild to moderate erectile dysfunction.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study found that platelet-rich plasma may be an effective adjuvant treatment for androgenetic alopecia, especially when combined with antiandrogenetic medications and topical minoxidil, though factors like patient age and family history could influence outcomes.

In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

This study concluded that blood donors on certain medications can donate blood products with less than 50 ml single-donor plasma for adult use without deferral, except for those taking specific medications like retinoids and genotoxic drugs.

This study reported that an injectable hydrogel based on platelet-rich plasma and laponite improved wound healing in diabetic and normal rats by enhancing angiogenesis and macrophage polarization.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

This study found that platelet-rich plasma can transiently inhibit bacterial growth in vitro against multidrug-resistant strains from diabetic foot infections, although its efficacy diminished over time and did not affect biofilm formation.

This case study identified non-criteria antiphospholipid syndrome as a potential underlying cause of Budd-Chiari syndrome in a patient, emphasizing the need for its consideration, especially in cases with multiple thromboemboli and thrombocytopenia.

This review discusses platelet-rich plasma as a treatment for hair loss and reports no clinical results; the authors note its potential as a minimally invasive option alongside existing therapies.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

This study developed a legally valid, evidence-based informed consent document specifically for platelet-rich plasma injections, intended to enhance patient rights and communication, and support legal defense in malpractice cases.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

In this case study, ischemic stroke occurred in a 20-year-old male taking finasteride for hair loss, with multiple genetic predispositions for thrombosis; while causality is uncertain, clinicians should exercise caution when prescribing finasteride to patients with thrombotic risk factors.

This study found that PLX, a mixture of tomato extract and chitooligosaccharide, may reduce prostate weight in testosterone-induced BPH in rats, suggesting it could act as a 5α-reductase inhibitor.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.

In this study, both platelet-rich plasma gel and 1% phenytoin cream showed comparable results for wound healing in diabetic foot ulcers in rats, with PRP providing slightly advanced histological improvements; however, the differences were not statistically significant.

In this study, injecting platelet-rich plasma into the muscular layer of the intestinal wall in rabbits significantly reduced adhesion development compared to soaking methods, suggesting an improvement in anastomosis regeneration.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This study found that a single dose of PRP with 100 billion platelets significantly reduced pain and improved knee function in patients with osteoarthritis, but did not alter joint structure on MRI.

In this study, finasteride significantly reduced plasma cholesterol and triglycerides and decreased atherosclerotic lesion burden in mice, suggesting its potential role in delaying cardiovascular disease.

This review discusses the use of platelet-rich plasma in aesthetic treatments, emphasizing its benefits and potential as a promising and safe alternative for enhancing appearance and self-confidence, without presenting new clinical results.